<ul><li>The US administration's latest measures against pharma imports might not impact India heavily since generics outside narcotics are likely not in focus.</li><li>Pharmexcil, an Export Promotion Council, stated that the measures seem more focused on opioid-based drugs and will not impact generics outside the narcotics category.</li><li>India exports approximately $9 billion worth of pharmaceuticals to the US, supplying around 40% of all generic drugs used in the country.</li><li>President Donald Trump initiated a Section 232 investigation over the US' heavy reliance on foreign drug manufacturing.</li></ul>

Trump's Pharma Measures Seem More Opioid-Focused, Won't Impact Majority Generics: Pharmexcil

Discover more